Compare BOSC & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOSC | XCUR |
|---|---|---|
| Founded | 1990 | 2011 |
| Country | Israel | United States |
| Employees | N/A | 8 |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.7M | 26.6M |
| IPO Year | 2002 | 2017 |
| Metric | BOSC | XCUR |
|---|---|---|
| Price | $4.61 | $4.34 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 61.7K | 18.2K |
| Earning Date | 03-31-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 83.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.97 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.30 | $3.10 |
| 52 Week High | $6.72 | $13.37 |
| Indicator | BOSC | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | 40.80 | 43.88 |
| Support Level | $4.21 | $3.40 |
| Resistance Level | $5.11 | $4.34 |
| Average True Range (ATR) | 0.22 | 0.34 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 29.71 | 0.00 |
BOS Better Online Solutions Ltd is a provider of Intelligent Robotics and Supply Chain solutions for enterprises. The company manages its business in three reportable divisions: the Intelligent Robotics segment, the RFID Division segment, and the Supply Chain Solutions segment. The majority of revenue derives from Supply Chain Solutions which distributes electro-mechanical components, mainly to customers in the aerospace, defense, and other industries, and is a supply chain service provider for aviation customers that seek a comprehensive solution to their components-supply needs. Geographically company derives the majority of its revenue from Israel.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.